|
|
Volumn 22, Issue 12, 2004, Pages 1496-
|
|
The biotech drug market
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
ANTIDIABETIC AGENT;
ANTINEOPLASTIC AGENT;
ARMODAFINIL;
BETA1A INTERFERON;
BEVACIZUMAB;
CETUXIMAB;
EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
ERLOTINIB;
ERYTHROPOIETIN;
ESZOPICLONE;
ETANERCEPT;
EXENDIN 4;
GENERIC DRUG;
GLATIRAMER;
HUMAN GROWTH HORMONE;
INDIPLON;
INFLIXIMAB;
INTERFERON BETA SERINE;
LENALIDOMIDE;
NATALIZUMAB;
NEW DRUG;
NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;
PEGINTERFERON ALPHA2A;
PEPTIDE;
RECOMBINANT ALPHA INTERFERON;
RECOMBINANT ERYTHROPOIETIN;
RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;
RECOMBINANT HORMONE;
RECOMBINANT PARATHYROID HORMONE;
SORAFENIB;
TENOFOVIR DISOPROXIL;
TRASTUZUMAB;
AGRICULTURE;
BIOTECHNOLOGY;
CLINICAL TRIAL;
COMPENSATION;
DRUG APPROVAL;
DRUG INDICATION;
DRUG MARKETING;
DRUG RESEARCH;
FOOD AND DRUG ADMINISTRATION;
FOOD BIOTECHNOLOGY;
HUMAN;
NOTE;
ORGANIZATION;
PATENT;
PRIORITY JOURNAL;
BIOTECHNOLOGY;
DRUG APPROVAL;
DRUG COMPOUNDING;
DRUG INDUSTRY;
MARKETING;
UNITED STATES;
HUMAN IMMUNODEFICIENCY VIRUS;
|
|
EID: 19944404712
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/nbt1204-1496 Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|